Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPVd in relapsed/refractory multiple myeloma
ChiCTR2200059910Phase 4Recruiting
- Sponsor
- Department of Hematology, Second Affiliated Hospital of Anhui Medical University
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bendamustine, pomalidomide, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Department of Hematology, Second Affiliated Hospital of Anhui Medical University. Primary endpoint: progression-free survival. Started Apr 2022; status: recruiting.
02
Drugs
bendamustinepomalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2200059910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059910.